Quarterly ResultMay 5, 2026, 07:08 AM
Q32 Bio Q1 Net Loss $7.6M; Cash Runway into 1H'2028
AI Summary
Q32 Bio Inc. reported its first quarter 2026 financial results, with a reduced net loss of $7.6 million, or $0.54 per share, compared to $11.0 million, or $0.90 per share, in the prior year. The company strengthened its financial position by completing a $10.5 million registered direct offering and receiving $14.2 million from its ATM program, extending its cash runway into the first half of 2028. Operationally, the SIGNAL-AA Phase 2a clinical trial for bempikibart remains on track for a mid-2026 data readout, and the first patient has been dosed in the Part B open-label extension.
Key Highlights
- Q1 2026 net loss was $7.6 million, down from $11.0 million in Q1 2025.
- Net loss per share was $0.54 for Q1 2026, compared to $0.90 in Q1 2025.
- Cash and cash equivalents totaled $50.8 million as of March 31, 2026.
- Financial runway extended into the first half of 2028.
- Completed $10.5 million registered direct offering in February 2026.
- Received $14.2 million gross proceeds from ATM program after quarter end.
- R&D expenses decreased to $3.2 million in Q1 2026 from $7.1 million in Q1 2025.
- G&A expenses decreased to $4.5 million in Q1 2026 from $5.1 million in Q1 2025.